These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 623118)

  • 1. Recommendations for the labeling of large volume parenterals. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1978 Jan; 35(1):49-51. PubMed ID: 623118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations to pharmacists for solving problems with large-volume parenterals-1979. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1980 May; 37(5):663-7. PubMed ID: 7386474
    [No Abstract]   [Full Text] [Related]  

  • 3. Recommended standards of practice, policies, and procedures for intravenous therapy. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1980 May; 37(5):660-3. PubMed ID: 7386473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommended procedures for in-use testing of large volume parenterals suspected of contamination or of producing a reaction in a patient. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1978 Jun; 35(6):678-82. PubMed ID: 665681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recommended system for surveillance and reporting of problems with large-volume parenterals in hospitals.
    Am J Hosp Pharm; 1975 Dec; 32(12):1251-3. PubMed ID: 1211398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aluminum in large and small volume parenterals used in total parenteral nutrition--FDA. Proposed rule.
    Fed Regist; 1998 Jan; 63(2):176-85. PubMed ID: 10176836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommended guidelines for quality assurance in hospital centralized intravenous admixture services. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1980 May; 37(5):645-55. PubMed ID: 7386471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations to pharmacists for solving problems with large-volume parenterals.
    Am J Hosp Pharm; 1976 Mar; 33(3):231-6. PubMed ID: 816199
    [No Abstract]   [Full Text] [Related]  

  • 9. Experts examine problems with labels on parenteral infusion products.
    Young D
    Am J Health Syst Pharm; 2007 Feb; 64(4):345-6. PubMed ID: 17299169
    [No Abstract]   [Full Text] [Related]  

  • 10. Recommended methods for compounding intravenous admixtures in hospitals.
    Am J Hosp Pharm; 1975 Mar; 32(3):261-70. PubMed ID: 1136973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assuring quality and performance of sustained and controlled release parenterals: AAPS workshop report, co-sponsored by FDA and USP.
    Burgess DJ; Hussain AS; Ingallinera TS; Chen ML
    Pharm Res; 2002 Nov; 19(11):1761-8. PubMed ID: 12458685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of particulate matter in large volume parenterals.
    Krueger EO
    Bull Parenter Drug Assoc; 1972; 26(2):96-100. PubMed ID: 5012209
    [No Abstract]   [Full Text] [Related]  

  • 13. Overfill of large volume parenterals.
    Turco S; Maza D; Ravin C
    Hosp Pharm; 1978 Jun; 13(6):338, 364. PubMed ID: 10307645
    [No Abstract]   [Full Text] [Related]  

  • 14. PDA response. FDA advance notice of proposed rulemaking on electronic identification/signatures. Parenteral Drug Association.
    J Parenter Sci Technol; 1993; 47(1):4-8. PubMed ID: 8445499
    [No Abstract]   [Full Text] [Related]  

  • 15. Standard administration labels for drugs administered by continuous infusion.
    Lucarotti RL; Jennings RH
    Hosp Pharm; 1982 Nov; 17(11):605-7. PubMed ID: 10257547
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA inspections of large volume and small volume parenteral manufacturers.
    Shepherd RE
    Bull Parenter Drug Assoc; 1976; 30(5):209-13. PubMed ID: 974306
    [No Abstract]   [Full Text] [Related]  

  • 17. Prescription drug products; patient package insert requirements--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(1):28-30. PubMed ID: 10324121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary pharmaceuticals manufacturing.
    Burling JN; Shah PV
    Occup Med; 1997; 12(1):29-48. PubMed ID: 9153051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
    Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA transparency rules could hit small companies hardest.
    Allison M
    Nat Biotechnol; 2010 Aug; 28(8):767-8. PubMed ID: 20697386
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.